RxDoctor Payments DataLook up a doctor →

John Britton, MD

Urology · Charleston, SCNPI 1356394126

Payments from drug & device makers

$14,772in general payments, 2019–2025

Across 441 payments — averaging $33.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$4K
  • Dendreon Pharmaceuticals LLC$1K
  • Astellas Pharma US Inc$963
  • Angiodynamics, Inc.$917
  • Merck$712
  • Procept Biorobotics Corporation$578
  • plus $7K from 51 others

What the payments were for

  • Consulting fees$2,77819%
  • Travel & lodging$5484%
  • Food & beverage$11,29276%
  • Education$1551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,772 in reported general payments places this provider in the 85th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$666,211
Medicare patients
1,155
Services billed
19,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide82$1,041,319
OrgovyxRelugolix84$218,665
XtandiEnzalutamide20$190,859
Abiraterone Acetate44$154,344
MyrbetriqMirabegron151$139,706
GemtesaVibegron66$62,236
XgevaDenosumab13$44,981
Testosterone59$8,967
Tamsulosin Hcl405$7,724
Finasteride412$6,670
Potassium Citrate ErPotassium Citrate51$4,267
Methenamine Hippurate66$4,182
Oxybutynin Chloride ErOxybutynin Chloride115$3,504
Dutasteride39$2,470
Estradiol28$2,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$3,719$1,041,31982 claims
Astellas Pharma US IncXtandi, Myrbetriq$963$330,565171 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$400$280,900150 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$38$154,34444 claims
AmgenXgeva$67$44,98113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 196 urology providers in South Carolina.

Other urology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →